Synonym
NVP-BVU972; NVP-BVU 972; NVP-BVU-972; BVU-972; BVU 972; BVU972.
IUPAC/Chemical Name
6-[[6-(1-methylpyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]methyl]quinoline
InChi Key
RNCNPRCUHHDYPC-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H16N6/c1-25-13-16(11-23-25)19-6-7-20-22-12-17(26(20)24-19)10-14-4-5-18-15(9-14)3-2-8-21-18/h2-9,11-13H,10H2,1H3
SMILES Code
CN1N=CC(C2=NN3C(C=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
NVP-BVU972 is an selective and potent Met inhibitor, with an IC50 of 14 nM.
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
84.0 |
246.78 |
| Ethanol |
68.0 |
200.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
340.39
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Shin JS, Hong SW, Moon JH, Kim JS, Jung KA, Kim SM, Lee DH, Kim I, Yoon SJ,
Lee CG, Choi EK, Lee JY, Kim KP, Hong YS, Lee JL, Kim B, Choi EK, Lee JS, Jin DH,
Kim TW. NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and
its constitutively active mutants. Invest New Drugs. 2014 Jun;32(3):389-99. doi:
10.1007/s10637-013-0039-4. Epub 2013 Oct 31. PubMed PMID: 24173966.
2: Tiedt R, Degenkolbe E, Furet P, Appleton BA, Wagner S, Schoepfer J, Buck E,
Ruddy DA, Monahan JE, Jones MD, Blank J, Haasen D, Drueckes P, Wartmann M,
McCarthy C, Sellers WR, Hofmann F. A drug resistance screen using a selective MET
inhibitor reveals a spectrum of mutations that partially overlap with activating
mutations found in cancer patients. Cancer Res. 2011 Aug 1;71(15):5255-64. doi:
10.1158/0008-5472.CAN-10-4433. Epub 2011 Jun 22. PubMed PMID: 21697284.
